Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-29

Clinical Trial Update: MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for MLN0128 in recurrent/metastatic Merkel cell carcinoma (Phase 1/Phase 2) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MLN0128 (sapanisertib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-29